Aptevo Therapeutics Gross Profit 2014-2022 | APVO
Aptevo Therapeutics gross profit from 2014 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Aptevo Therapeutics Annual Gross Profit
(Millions of US $) |
| 2021 |
$12 |
| 2020 |
$4 |
| 2019 |
$ |
| 2018 |
$12 |
| 2017 |
$10 |
| 2016 |
$-2 |
| 2015 |
$17 |
| 2014 |
$29 |
| 2013 |
$ |
Aptevo Therapeutics Quarterly Gross Profit
(Millions of US $) |
| 2022-03-31 |
$3 |
| 2021-12-31 |
$4 |
| 2021-09-30 |
$3 |
| 2021-06-30 |
$3 |
| 2021-03-31 |
$2 |
| 2020-12-31 |
$2 |
| 2020-09-30 |
$1 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
$2 |
| 2018-09-30 |
$3 |
| 2018-06-30 |
$4 |
| 2018-03-31 |
$2 |
| 2017-12-31 |
$1 |
| 2017-09-30 |
$4 |
| 2017-06-30 |
$1 |
| 2017-03-31 |
$4 |
| 2016-12-31 |
$-9 |
| 2016-09-30 |
$-1 |
| 2016-06-30 |
$4 |
| 2016-03-31 |
$5 |
| 2015-12-31 |
|
| 2015-09-30 |
$3 |
| 2015-06-30 |
$3 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.018B |
$0.012B |
|
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
|
